On December 5, 2025, GUSHENGTANG (02273) held its Annual Expert Appreciation and Technology & Innovation Development Conference in Beijing. The event brought together top experts in traditional Chinese medicine (TCM) and artificial intelligence (AI) to witness the announcement of multiple strategic collaborations and achievements. These included the signing of a TCM AI model partnership, the launch of an integrated clinical research platform, and the introduction of the "National TCM AI Brain." Additionally, GUSHENGTANG entered a strategic collaboration with AutoNavi and acquired 100% equity in Singapore China TCM, covering four key areas: AI model R&D, clinical research, traffic ecosystem development, and overseas expansion. These initiatives highlight GUSHENGTANG's comprehensive strategy to modernize TCM and inject new momentum into the industry.
Tu Zhiliang, Founder and Chairman of GUSHENGTANG, emphasized in his speech, "Promoting the modernization and globalization of TCM is not only a response to national policy but also a strategic imperative for GUSHENGTANG. Our investments in AI and overseas markets aim to expand the supply and service capabilities of high-quality TCM resources." He outlined an ambitious global expansion plan, targeting entry into Hong Kong and Malaysia by 2026, followed by expansion into Europe and the U.S.
The conference was attended by nearly 1,000 guests, including renowned TCM experts, AI researchers, and industry leaders, with over 10 regional branches participating via livestream.
### **1. Collaborating with Top Research Teams to Build a Benchmark TCM AI Model** A major highlight was GUSHENGTANG's partnership with four leading research teams—led by Professor Sun Maosong (Tsinghua University), Professor Gu Xiaohong (Beijing University of Chinese Medicine), Professor Liu Baoyan (China Academy of Chinese Medical Sciences), and Professor Zhou Xuezhong (Beijing Jiaotong University). Together, they will develop specialized TCM AI models and intelligent agents.
The collaboration focuses on five key areas: - Developing an AI model tailored to TCM diagnostics. - Establishing a rigorous evaluation system for TCM AI with authoritative institutions. - Creating AI-assisted diagnosis and patient health management tools. - Integrating classical TCM texts, medical records, and expert cases for model training. - Publishing high-level academic research in top journals.
GUSHENGTANG also unveiled the "National TCM AI Brain," a second-phase product that provides real-time clinical decision support for young doctors. Currently in trial operation, it assists in specialties like gastroenterology, oncology, and ENT.
Professor Sun Maosong praised the initiative, stating that GUSHENGTANG’s systematic approach sets a clear path for TCM modernization.
### **2. Launching an Integrated Clinical Research Platform to Accelerate TCM Drug Development** GUSHENGTANG, in collaboration with top research institutions, launched a clinical research platform to address real-world TCM data challenges. The platform will streamline data governance, efficacy validation, and application.
To date, GUSHENGTANG has completed 16 proprietary drug filings, including the HSA-certified "Hair Growth Granules" in Singapore. The platform is expected to yield more affordable and effective TCM drugs for patients.
### **3. Expanding Global Footprint and Traffic Ecosystem** GUSHENGTANG is strengthening its digital and global presence. A strategic partnership with AutoNavi will integrate TCM services with navigation and local lifestyle scenarios, enhancing accessibility. The company has also partnered with Meituan, Douyin, and Xiaohongshu to build a multi-dimensional online traffic matrix.
For global expansion, GUSHENGTANG adopted a "M&A + Partnerships + Self-Building" strategy. The acquisition of Singapore China TCM’s 14 clinics will increase its Singapore footprint to 16 locations, leveraging the brand’s established operations.
### **Conclusion** From AI-driven diagnostics to global expansion, GUSHENGTANG’s initiatives demonstrate a holistic growth strategy. As these collaborations materialize, the company is poised to reinforce its leadership in TCM and drive industry innovation.
Comments